PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29276624-2	2017	Objective: The objective of this paper is to assess the effect of IFN beta-1a and placebo on CBH evolution and disability in patients with relapsing-remitting multiple sclerosis (RRMS), as well as CBH evolution in patients with secondary progressive multiple sclerosis (SPMS).	S-(D-CARBOXYBUTYL)-L-HOMOCYSTEINE	93-96	interferon alpha 1	Homo sapiens	66-69	
29276624-4	2017	Results: In RRMS patients, the risk of >=1 evolved CBH was lower for IFN beta-1a versus placebo (odds ratio 0.42; p = 0.024); volume of newly evolved CBH was numerically reduced.	S-(D-CARBOXYBUTYL)-L-HOMOCYSTEINE	54-57	interferon alpha 1	Homo sapiens	72-75